Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01830621




Registration number
NCT01830621
Ethics application status
Date submitted
10/04/2013
Date registered
12/04/2013
Date last updated
28/08/2023

Titles & IDs
Public title
BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma
Scientific title
A Phase III Randomized Study of BBI608 and Best Supportive Care Versus Placebo and Best Supportive Care in Patients With Pretreated Advanced Colorectal Carcinoma
Secondary ID [1] 0 0
CO23
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Colorectal Carcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Bowel - Back passage (rectum) or large bowel (colon)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BBI608
Treatment: Drugs - Placebo
Other interventions - Best Supportive Care

Active Comparator: BBI608 - BBI608 480 mg two times daily (960 mg total daily dose)+ Best Supportive Care

Placebo Comparator: Placebo - Placebo two times daily + Best Supportive Care


Treatment: Drugs: BBI608


Treatment: Drugs: Placebo


Other interventions: Best Supportive Care
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival
Timepoint [1] 0 0
36 month
Secondary outcome [1] 0 0
Progression Free Survival
Timepoint [1] 0 0
36 months
Secondary outcome [2] 0 0
Disease Control Rate
Timepoint [2] 0 0
36 months
Secondary outcome [3] 0 0
Number of Patients With Adverse Events
Timepoint [3] 0 0
36 months
Secondary outcome [4] 0 0
Change of Global Quality of Life at 8 Weeks From Baseline
Timepoint [4] 0 0
8 weeks

Eligibility
Key inclusion criteria
- Histologically confirmed advanced colorectal cancer that is unresectable.

- Received a prior thymidylate synthase inhibitor (e.g. 5-fluorouracil (5-FU),
capecitabine, raltitrexed, UFT) for metastatic disease or as adjuvant therapy.

- Received and failed an irinotecan containing regimen (i.e. single-agent or in
combination) for treatment of metastatic disease, OR relapsed within 6 months of
completion of an irinotecan-containing adjuvant therapy, OR have documented
unsuitability for an irinotecan-containing regimen.

- Received and failed an oxaliplatin-containing regimen for treatment of metastatic
disease, OR relapsed within 6 months of completion of an oxaliplatin-containing
adjuvant therapy OR have documented unsuitability for an oxaliplatin-containing
regimen.

- For patients with colorectal cancer that is K-ras wild type: Received and failed a
cetuximab or panitumumab-containing regimen (i.e. single-agent or in combination) for
treatment of metastatic disease OR have documented unsuitability for a cetuximab or
panitumumab-containing regimen

- The only remaining standard available therapy as recommended by the Investigator is
best supportive care.

- Must have presence of measurable disease as defined by Response Evaluation Criteria in
Solid Tumours (RECIST 1.1).

- Imaging investigations including CT/MRI of chest/abdomen/pelvis or other scans as
necessary to document all sites of disease done within 14 days prior to randomization.

- Must have an ECOG Performance Status of 0 or 1.

- Must be = 18 years of age.

- For male or female patient of child producing potential: Must agree to use
contraception or take measures to avoid pregnancy during the study and for 30 days
after the last Protocol treatment dose.

- Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy
test within 72 hours prior to randomization.

- Must have alanine transaminase (ALT) = 3 × institutional upper limit of normal (ULN)
[= 5 × ULN in presence of liver metastases] within 14 days prior to randomization.

- Must have hemoglobin (Hgb) = 80 g/L within 14 days prior to randomization.

- Must have total bilirubin = 1.5 × institutional ULN [= 2.0 x ULN in presence of liver
metastases] within 14 days prior to randomization.

- Must have creatinine = 1.5 × institutional ULN or Creatinine Clearance > 50 ml/min
within 14 days prior to randomization.

- Must have absolute neutrophil count = 1.5 x 109/L within 14 days prior to
randomization.

- Must have platelet count = 75 x 109/L within 14 days prior to randomization.

- Other biochemistry which must be done within 14 days prior to randomization includes
lactate dehydrogenase (LDH) and alkaline phosphatase.

- Patient must consent to provision of, and investigator(s) must confirm access to and
agree to submit at the request of the NCIC CTG Central Tumour Bank, a representative
formalin fixed paraffin block of tumour tissue in order that the specific correlative
marker assays may be conducted.

- Patient must consent to provision of a sample of blood in order that the specific
correlative marker assays may be conducted.

- Patient is able (i.e. sufficiently fluent) and willing to complete the Quality of Life
and Health Utilities questionnaires in one of the validated languages for the
questionnaires.

- Patients must be accessible for treatment and follow-up. Patients registered on this
trial must be treated and followed at the participating centre. This implies there
must be reasonable geographical limits placed on patients being considered for this
trial.

- Protocol treatment is to begin within 2 working days of patient randomization.

- The patient is not receiving therapy in a concurrent clinical study and the patient
agrees not to participate in other clinical studies during their participation in this
trial while on study treatment.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Anti-cancer chemotherapy or biologic therapy within the lesser of i) 21 days, or ii)
the usual cycle length of the regimen (e.g. 14 days for FOLFOX), prior to the first
planned dose of BBI608/placebo. An exception is made for capecitabine and regorafenib,
where a minimum of 10 days since last dose must be observed prior to the first planned
dose of BBI608/placebo.

- Radiotherapy, immunotherapy, or investigational agents within four weeks of first
planned dose of BBI608/placebo, with the exception of a single dose of radiation up to
8 Gray (equal to 800 RAD) with palliative intent for pain control up to 14 days before
randomization.

- Major surgery within 4 weeks prior to randomization.

- Any known symptomatic brain metastases requiring steroids.

- Women who are pregnant or breastfeeding.

- Gastrointestinal disorder(s) which, in the opinion of the Qualified/Principal
Investigator, would significantly impede the absorption of an oral agent (e.g. active
Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection).

- Unable or unwilling to swallow BBI608/placebo capsules daily.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, clinically significant non-healing or healing wounds, symptomatic
congestive heart failure, unstable angina pectoris, clinically significant cardiac
arrhythmia, significant pulmonary disease (shortness of breath at rest or mild
exertion), uncontrolled infection or psychiatric illness/social situations that would
limit compliance with study requirements.

- Patients with a history of other malignancies except: adequately treated non-melanoma
skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours
curatively treated with no evidence of disease for = 5 years.

- Prior treatment with BBI608.

- Any active disease condition which would render the protocol treatment dangerous or
impair the ability of the patient to receive protocol therapy.

- Any condition (e.g. psychological, geographical, etc.) that does not permit compliance
with the protocol.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
10/05/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
16/05/2016
Sample size
Target
Accrual to date
Final
282
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC,WA
Recruitment hospital [1] 0 0
Bankstown/ Lidcombe - Bankstown
Recruitment hospital [2] 0 0
Townsville Hospital - Douglas
Recruitment hospital [3] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [4] 0 0
Lyell McEwin Hospital - Elizabeth Vale
Recruitment hospital [5] 0 0
The Queen Elizabeth Hospital - Woodville South
Recruitment hospital [6] 0 0
Royal Hobart Hospital - Hobart
Recruitment hospital [7] 0 0
Peter MacCallum Cancer Institute - East Melbourne
Recruitment hospital [8] 0 0
St John of God - Subiaco - Subiaco
Recruitment hospital [9] 0 0
St John of God Bunbury Hospital - Bunbury
Recruitment postcode(s) [1] 0 0
2200 - Bankstown
Recruitment postcode(s) [2] 0 0
4814 - Douglas
Recruitment postcode(s) [3] 0 0
5042 - Bedford Park
Recruitment postcode(s) [4] 0 0
5112 - Elizabeth Vale
Recruitment postcode(s) [5] 0 0
5011 - Woodville South
Recruitment postcode(s) [6] 0 0
7000 - Hobart
Recruitment postcode(s) [7] 0 0
3002 - East Melbourne
Recruitment postcode(s) [8] 0 0
6008 - Subiaco
Recruitment postcode(s) [9] 0 0
6230 - Bunbury
Recruitment outside Australia
Country [1] 0 0
Canada
State/province [1] 0 0
Alberta
Country [2] 0 0
Canada
State/province [2] 0 0
British Columbia
Country [3] 0 0
Canada
State/province [3] 0 0
Manitoba
Country [4] 0 0
Canada
State/province [4] 0 0
New Brunswick
Country [5] 0 0
Canada
State/province [5] 0 0
Newfoundland and Labrador
Country [6] 0 0
Canada
State/province [6] 0 0
Nova Scotia
Country [7] 0 0
Canada
State/province [7] 0 0
Ontario
Country [8] 0 0
Canada
State/province [8] 0 0
Quebec
Country [9] 0 0
Canada
State/province [9] 0 0
Saskatchewan
Country [10] 0 0
Japan
State/province [10] 0 0
Chiba
Country [11] 0 0
Japan
State/province [11] 0 0
Fukuoka
Country [12] 0 0
Japan
State/province [12] 0 0
Kashiwa
Country [13] 0 0
Japan
State/province [13] 0 0
Kobe
Country [14] 0 0
Japan
State/province [14] 0 0
Matsuyama
Country [15] 0 0
Japan
State/province [15] 0 0
Mitaka
Country [16] 0 0
Japan
State/province [16] 0 0
Nagoya
Country [17] 0 0
Japan
State/province [17] 0 0
Osaka
Country [18] 0 0
Japan
State/province [18] 0 0
Saitama
Country [19] 0 0
Japan
State/province [19] 0 0
Sapporo
Country [20] 0 0
Japan
State/province [20] 0 0
Shizuoka
Country [21] 0 0
Japan
State/province [21] 0 0
Takatsuki
Country [22] 0 0
Japan
State/province [22] 0 0
Tokyo

Funding & Sponsors
Primary sponsor type
Other
Name
NCIC Clinical Trials Group
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Sumitomo Pharma America, Inc.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to find out whether it is better to receive a new drug, BBI608,
or better to receive no further treatment for colon or rectal cancer. To do this, half of the
patients in this study will get BBI608 and the other half will receive a placebo (a substance
that is designed not to do anything).
Trial website
https://clinicaltrials.gov/ct2/show/NCT01830621
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Derek Jonker
Address 0 0
Ottawa Health Research Institute - General Division
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01830621